EGFR and non-small cell lung carcinoma: Relatedly, for patients with advanced EGFR‐mutant NSCLC, EGFR tyrosine kinase inhibitors (TKIs) have yielded improved objective response rates and progression‐free survival (PFS) compared with chemotherapy.2